GSK drug fails in lung patients

Share this article:

GlaxoSmithKline's immunotherapy MAGE-A3 cancer drug has failed among non-small cell lung cancer patients in a Phase III clinical trial. The company announced Thursday that the drug failed to significantly extend disease-free survival among patients its target groups. Bloomberg notes that this is the second time the drug has failed among advanced cancer patients.

The company said it is will continue with a third endpoint that was part of this trial—one that focuses on a subset of patients (those who are MAGE-A3 positive)—who may benefit from the treatment.

GSK said it is also continuing with another clinical study using this same drug, but in melanoma patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.